Wealth Advisors of Tampa Bay LLC Takes $4.31 Million Position in Eli Lilly and Co (LLY)
Wealth Advisors of Tampa Bay LLC acquired a new stake in Eli Lilly and Co (NYSE:LLY) in the 4th quarter, Holdings Channel reports. The fund acquired 49,897 shares of the company’s stock, valued at approximately $4,307,000. Eli Lilly and accounts for 3.0% of Wealth Advisors of Tampa Bay LLC’s holdings, making the stock its 10th biggest holding.
Several other institutional investors and hedge funds have also modified their holdings of LLY. Beach Investment Management LLC. acquired a new position in Eli Lilly and during the 2nd quarter worth approximately $400,000. Jennison Associates LLC raised its stake in shares of Eli Lilly and by 13.9% during the 2nd quarter. Jennison Associates LLC now owns 1,947,061 shares of the company’s stock worth $160,243,000 after purchasing an additional 237,342 shares in the last quarter. Investment Management of Virginia LLC raised its stake in shares of Eli Lilly and by 1.0% during the 2nd quarter. Investment Management of Virginia LLC now owns 11,645 shares of the company’s stock worth $958,000 after purchasing an additional 110 shares in the last quarter. Marshall Wace North America L.P. raised its stake in shares of Eli Lilly and by 571.7% during the 2nd quarter. Marshall Wace North America L.P. now owns 387,014 shares of the company’s stock worth $31,735,000 after purchasing an additional 329,393 shares in the last quarter. Finally, Boston Family Office LLC raised its stake in shares of Eli Lilly and by 0.9% during the 2nd quarter. Boston Family Office LLC now owns 10,580 shares of the company’s stock worth $871,000 after purchasing an additional 90 shares in the last quarter. Institutional investors and hedge funds own 76.20% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 259,610 shares of company stock worth $22,727,406. 0.20% of the stock is currently owned by corporate insiders.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same period in the previous year, the company posted $0.95 EPS. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. research analysts anticipate that Eli Lilly and Co will post 4.88 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.95%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently -1,040.00%.
LLY has been the topic of a number of analyst reports. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 5th. Finally, Bank of America dropped their price target on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday, February 1st. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $92.02.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/02/12/wealth-advisors-of-tampa-bay-llc-takes-4-31-million-position-in-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.